UM
MRNA icon

Ulysses Management’s Moderna MRNA Stock Holding History

Ulysses Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,100
Closed -$620K – 53
2023
Q2 		$620K Buy
+5,100
New +$680K 0.06% 41
2023
Q1 		– Sell
-6,000
Closed -$1.08M – 56
2022
Q4 		$1.08M Sell
6,000
-3,000
-33% -$491K 0.26% 30
2022
Q3 		$1.06M Buy
+9,000
New +$1.37M 0.15% 33

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Ulysses Management's MRNA Position: Q3 2023 in Review

Ulysses Management sold out of Moderna (MRNA) in Q3 2023, closing a stake of 5,100 shares — an estimated $620K sold.

Ulysses Management first reported a position in MRNA in Q3 2022 and held it in 3 quarters. The position peaked at $1.08M in Q4 2022. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Ulysses Management reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • Ulysses Management sold 5,100 Moderna shares in Q3 2023, an estimated $620K.
  • Ulysses Management first reported a position in Moderna in Q3 2022 and held it in 3 quarters.
  • Ulysses Management's Moderna position peaked at $1.08M in Q4 2022.
  • 889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Ulysses Management's 13F filing for Q3 2023, filed 14 Nov 2023.